Background: Mononuclear phagocytes, such as monocytes, macrophages, and dendritic cells, are important cellular components of the innate immune system that contribute to the pathogenesis of many intestinal inflammatory diseases. Summary: While mononuclear phagocytes play a key role in the induction of inflammation in many different tissues through production of pro-inflammatory cytokines and chemokines (such as IL-1, TNF, IL-6, IL-8 and MCP-1), free oxygen radicals (also termed ‘oxidative burst'), proteases (such as cathepsins) and tissue-degrading enzymes (such as metalloproteinases), resident macrophages as well as dendritic cells in the intestine display an anergic and ‘tolerogenic' phenotype mediating tolerance to commensal bacteria. In recent years many single nucleotide polymorphisms (SNPs) in genes mainly expressed in the above-mentioned cell types have been identified to convey an increased risk of autoimmune diseases. SNPs in the NOD2, ATG16L1 and TNFSF15 genes, which are involved in the function of the innate immune cells, are identified as risk factors for Crohn's disease (CD). Of note, these genes are involved in the different functions in the innate immune cells. For example, while NOD2 is required for intracellular recognition of microbial components, ATG16L1 is involved in autophagy responses against intracellular microbes. Likewise, TNFSF15 contributes to the induction of inflammatory responses by innate immune cells. Furthermore, the frequency of mutations in these genes differs by ethnicity. Genetic variations in the NOD2 and ATG16L1 genes are associated with CD in Caucasians but much less in Eastern Asian populations, whereas SNPs in TNFSF15 are dominated in Asian populations. Thus, different genetic risks may eventually lead to similar impairments in innate immune cells, thereby developing the same disease in Western and Asian patients with CD. Key Messages: Despite differences in risk genes, similar mechanisms associated with the innate immune system may trigger autoimmune and chronic inflammatory intestinal diseases in East and West.

Keywords:
Chronic inflammation, Dendritic cells, Innate immunity, Macrophages, Single nucleotide polymorphisms
1.
Davies JM, Abreu MT: The innate immune system and inflammatory bowel disease. Scand J Gastroenterol 2015;50:24-33.
2.
Moretta A, Marcenaro E, Sivori S, et al: Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol 2005;26:668-675.
3.
Liddiard K, Taylor PR: Understanding local macrophage phenotypes in disease: shape-shifting macrophages. Nat Med 2015;21:119-120.
4.
Steinbach EC, Plevy SE: The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis 2014;20:166-175.
5.
Bain CC, Mowat AM: Macrophages in intestinal homeostasis and inflammation. Immunol Rev 2014;260:102-117.
6.
Mann ER, Li X: Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells. World J Gastroenterol 2014;20:9653-9664.
7.
Liu JZ, van Sommeren S, Huang H, et al: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979-986.
8.
Ellinghaus D, Bethune J, Petersen BS, et al: The genetics of Crohn's disease and ulcerative colitis - status quo and beyond. Scand J Gastroenterol 2015;50:13-23.
9.
Jostins L, Ripke S, Weersma RK, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
10.
Lees CW, Satsangi J: Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009;3:513-534.
11.
Lees CW, Barrett JC, Parkes M, et al: New IBD genetics: common pathways with other diseases. Gut 2011;60:1739-1753.
12.
Bain CC, Bravo-Blas A, Scott CL, et al: Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol 2014;15:929-937.
13.
Bain CC, Mowat AM: The monocyte-macrophage axis in the intestine. Cell Immunol 2014;291:41-48.
14.
Spoettl T, Hausmann M, Menzel K, et al: Role of soluble factors and three-dimensional culture in in vitro differentiation of intestinal macrophages. World J Gastroenterol 2007;13:1032-1041.
15.
Spöttl T, Hausmann M, Kreutz M, et al: Monocyte differentiation in intestine-like macrophage phenotype induced by epithelial cells. J Leukoc Biol 2001;70:241-251.
16.
Kamada N, Hisamatsu T, Okamoto S, et al: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008;118:2269-2280.
17.
Hausmann M, Bataille F, Spoettl T, et al: Physiological role of macrophage inflammatory protein-3 alpha induction during maturation of intestinal macrophages. J Immunol 2005;175:1389-1398.
18.
Hausmann M, Obermeier F, Schreiter K, et al: Cathepsin D is up-regulated in inflammatory bowel disease macrophages. Clin Exp Immunol 2004;136:157-167.
19.
Hausmann M, Spöttl T, Andus T, et al: Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. Clin Exp Immunol 2001;125:48-55.
20.
Rogler G, Hausmann M, Spöttl T, et al: T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. Eur J Gastroenterol Hepatol 1999;11:1105-1111.
21.
Rogler G, Hausmann M, Vogl D, et al: Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol 1998;112:205-215.
22.
Rogler G, Brand K, Vogl D, et al: Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-369.
23.
Rogler G, Andus T, Aschenbrenner E, et al: Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997;9:893-899.
24.
Kamada N, Hisamatsu T, Honda H, et al: Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J Immunol 2009;183:1724-1731.
25.
Italiani P, Boraschi D: From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 2014;5:514.
26.
Ziegler-Heitbrock L: Monocyte subsets in man and other species. Cell Immunol 2014;289:135-139.
27.
Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82.
28.
Wong KL, Yeap WH, Tai JJ, et al: The three human monocyte subsets: implications for health and disease. Immunol Res 2012;53:41-57.
29.
Weiss G, Schaible UE: Macrophage defense mechanisms against intracellular bacteria. Immunol Rev 2015;264:182-203.
30.
Sica A, Erreni M, Allavena P, et al: Macrophage polarization in pathology. Cell Mol Life Sci 2015;72:4111-4126.
31.
Motwani MP, Gilroy DW: Macrophage development and polarization in chronic inflammation. Semin Immunol 2015;27:257-266.
32.
Brandtzaeg P: Nature and function of gastrointestinal antigen-presenting cells. Allergy 2001;56(suppl 67):16-20.
33.
Schultze JL, Freeman T, Hume DA, et al: A transcriptional perspective on human macrophage biology. Semin Immunol 2015;27:44-50.
34.
Lawrence T, Natoli G: Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011;11:750-761.
35.
Hume DA, Wells CA, Ravasi T: Transcriptional regulatory networks in macrophages. Novartis Found Symp 2007;281:2-18; discussion 18-24, 50-53, 208-209.
36.
Hawiger J: Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 2001;23:99-109.
37.
Hausmann M, Kiessling S, Mestermann S, et al: Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002;122:1987-2000.
38.
Salem M, Seidelin JB, Eickhardt S, et al: Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. Clin Exp Immunol 2015;179:426-434.
39.
Smythies LE, Sellers M, Clements RH, et al: Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005;115:66-75.
40.
Kamada N, Hisamatsu T, Okamoto S, et al: Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol 2005;175:6900-6908.
41.
Hetzenecker AM, Seidl MC, Kosovac K, et al: Downregulation of the ubiquitin-proteasome system in normal colonic macrophages and reinduction in inflammatory bowel disease. Digestion 2012;86:34-47.
42.
Duerr RH: Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 2003;37:358-367.
43.
Vind I, Jespersgaard C, Hougs L, et al: Genetic and environmental factors in monozygotic twins with Crohn's disease and their first-degree relatives: a case report. Digestion 2005;71:262-265.
44.
Hampe J, Cuthbert A, Croucher PJ, et al: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-1928.
45.
Hugot JP, Chamaillard M, Zouali H, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
46.
Ogura Y, Bonen DK, Inohara N, et al: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
47.
Sugimura M, Kinouchi Y, Takahashi S, et al: CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease. Clin Genet 2003;63:160-162.
48.
Leong RW, Armuzzi A, Ahmad T, et al: NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 2003;17:1465-1470.
49.
Guo QS, Xia B, Jiang Y, et al: NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J Gastroenterol 2004;10:1069-1071.
50.
Brant SR, Wang MH, Rawsthorne P, et al: A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol 2007;102:313-323.
51.
Inoue N, Tamura K, Kinouchi Y, et al: Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91.
52.
Yamazaki K, Takazoe M, Tanaka T, et al: Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 2002;47:469-472.
53.
Girardin SE, Boneca IG, Viala J, et al: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-8872.
54.
Inohara N, Ogura Y, Fontalba A, et al: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003;278:5509-5512.
55.
Berrebi D, Maudinas R, Hugot JP, et al: Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 2003;52:840-846.
56.
Hisamatsu T, Suzuki M, Reinecker HC, et al: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
57.
Gutierrez O, Pipaon C, Inohara N, et al: Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002;277:41701-41705.
58.
Ogura Y, Lala S, Xin W, et al: Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003;52:1591-1597.
59.
Lala S, Ogura Y, Osborne C, et al: Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003;125:47-57.
60.
Uehara A, Fujimoto Y, Fukase K, et al: Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 2007;44:3100-3111.
61.
Voss E, Wehkamp J, Wehkamp K, et al: NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006;281:2005-2011.
62.
Kobayashi KS, Chamaillard M, Ogura Y, et al: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-734.
63.
Wehkamp J, Stange EF: A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. Ann NY Acad Sci 2006;1072:321-331.
64.
Prescott NJ, Fisher SA, Franke A, et al: A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 2007;132:1665-1671.
65.
Hampe J, Franke A, Rosenstiel P, et al: A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-211.
66.
Rioux JD, Xavier RJ, Taylor KD, et al: Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
67.
Barrett JC, Hansoul S, Nicolae DL, et al: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-962.
68.
Kakuta Y, Kinouchi Y, Negoro K, et al: Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut 2006;55:1527-1528.
69.
Yang SK, Lim J, Chang HS, et al: Association of TNFSF15 with Crohn's disease in Koreans. Am J Gastroenterol 2008;103:1437-1442.
70.
Gregersen PK, Olsson LM: Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009;27:363-391.
71.
Thompson AI, Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis 2011;17:831-848.
72.
Zhernakova A, van Diemen CC, Wijmenga C: Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009;10:43-55.
73.
Diaz-Gallo LM, Espino-Paisan L, Fransen K, et al: Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2011;17:2287-2294.
74.
Kyogoku C, Langefeld CD, Ortmann WA, et al: Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004;75:504-507.
75.
Michou L, Lasbleiz S, Rat AC, et al: Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci USA 2007;104:1649-1654.
76.
Begovich AB, Carlton VE, Honigberg LA, et al: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75:330-337.
77.
Bottini N, Musumeci L, Alonso A, et al: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004;36:337-338.
78.
Spalinger MR, McCole DF, Rogler G, et al: Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation. Inflamm Bowel Dis 2015;21:645-655.
79.
Spalinger MR, Rogler G, Scharl M: Crohn's disease: loss of tolerance or a disorder of autophagy? Dig Dis 2014;32:370-377.
80.
Orru V, Tsai SJ, Rueda B, et al: A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 2009;18:569-579.
81.
Rodriguez-Rodriguez L, Taib WR, Topless R, et al: The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples. Arthritis Rheum 2011;63:365-372.
82.
Vang T, Congia M, Macis MD, et al: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005;37:1317-1319.
83.
Arimura Y, Yagi J: Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells. Sci Signal 2010;3:rs1.
84.
Zhang J, Zahir N, Jiang Q, et al: The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011;43:902-907.
85.
Spalinger MR, Lang S, Vavricka SR, et al: Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy. PLoS One 2013;8: e72384.
86.
Spalinger MR, Lang S, Weber A, et al: Loss of protein tyrosine phosphatase nonreceptor type 22 regulates interferon-γ-induced signaling in human monocytes. Gastroenterology 2013;144:978-988.e10.
87.
Raki M, Tollefsen S, Molberg O, et al: A unique dendritic cell subset accumulates in the celiac lesion and efficiently activates gluten-reactive T cells. Gastroenterology 2006;131:428-438.
88.
Beitnes AC, Raki M, Brottveit M, et al: Rapid accumulation of CD14+CD11c+ dendritic cells in gut mucosa of celiac disease after in vivo gluten challenge. PLoS One 2012;7: e33556.
89.
Junker Y, Zeissig S, Kim SJ, et al: Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med 2012;209:2395-2408.
90.
Muller PA, Koscso B, Rajani GM, et al: Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 2014;158:300-313.
91.
Anitha M, Vijay-Kumar M, Sitaraman SV, et al: Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 2012;143:1006-1016.e4.
92.
Brun P, Giron MC, Qesari M, et al: Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology 2013;145:1323-1333.
93.
Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al: Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014;63:1737-1745.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.